Market research
TARA Protara Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 229M
- P/E ratio
- Not available
- Analyst target
- 25.7143
- Dividend yield
- Not available
- Beta
- 1.49
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74365U1079
- Market cap
- 229M
- P/E ratio
- Not available
- Analyst target
- 25.7143
- Dividend yield
- Not available
- Beta
- 1.49
About
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TARA discussion.
5 years, 4 months ago
Protara Therapeutics, Inc is currently in a long term downtrend where the price is trading 49.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Protara Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 97.9% to $-34K since the same quarter in the previous year.
Finally, its free cash flow fell by 6941.8% to $-222M since the same quarter in the previous year.
Based on the above factors, Protara Therapeutics, Inc gets an overall score of 2/5.